R

Clinical Implications of the EMERALD Data on Treatment Outcomes in HR+/HER2- mBC

By Robert Wesolowski
351 views
February 29, 2024
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
London Breast Meeting

London Breast Meeting 2024

Wed, Sep 4, 2024
12:35
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Appropriate 1L Therapy for ER+…

Feat. S. Tolaney, H. Rugo
14:16
Dana-Farber Cancer Institute

Year in Review: Breast Cancer

Feat. P. Tarantino
05:43
Total Health

Neoadjuvant Chemo for HR+ BC: Year in Review

Feat. C. Ma
10:27
Insights from 2023 SABCS

SABCS 2023 Summary: "What Is the Role for CDK 4/6i in the Adjuv…

Feat. S. Tolaney, H. Rugo
49:07
SABCS 2022 Conference Coverage

SABCS 2022 Expert Panel Discussion: Practice-Changing Updates

Feat. J. O'Shaughnessy, S. Tolaney, S. Hurvitz, H. Rugo
07:50
Oncology Data Advisor

ESMO 2023 Insights: "Real-World Use Patterns, Effectiveness, &a…

Feat. K. Kalinsky
17:35
Insights from 2023 SABCS

SABCS 2023 Summary: "Top 5 Studies Including KATHERINE & HE…

Feat. P. Tarantino
24:10
Keck School of Medicine of USC

CDK4/6 Inhibitors in Breast Cancer: 2024 Update

Feat. R. O'Regan
23:13
Keck School of Medicine of USC

NRG-BR009 ("OFSET") Study: Evaluating the Addition of Adju…

Feat. T. Mamounas
21:37
Dana-Farber Cancer Institute

Standard Treatments for HR+/HER2- mBC in 2023

Feat. S. Sammons
27:01
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

CDK4/6 Inhibitor Therapy in Early-Stage HR+/HER2- BC

Feat. S. Sammons
08:41
Insights from 2023 SABCS

SABCS 2023 Insights: "Analysis of ctDNA for the Detection of MR…

Feat. W. Janni
03:24
ecancer

SABCS 2022 EMERALD Phase 3 Trial: Elacestrant and PFS in ER+/HER2- m…

Feat. V. Kaklamani
12:24
Stanford Medicine

HR+ mBC: CDK4/6i Progression Management

Feat. M. Dolezal
11:19
Adam Brufsky

HER2+ mBC: The Role of TDM-1

29:44
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2023

Optimal Duration of Endocrine Therapy for Breast Cancer

Feat. V. Kaklamani
13:23
Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "A Pooled Analysis of T-DXd for HER2+ mBC Wi…

Feat. S. Hurvitz
20:42
Total Health

2022 Updates in TNBC

Feat. I. Schlam
18:11
Nagi El Saghir

ABC7 2023 International Consensus Guidelines: Select Guidelines for …

20:16
University of Colorado Cancer Center

Updated NCCN Guidelines for HR+/HER2- mBC: Treatment Options in 1L S…

Feat. V. Borges